Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer|
- Tumor stage change from Computed Tomography (CT) perfusion measurement [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Tumor perfusion as measured by perfusion CT. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
If the patient undergoes surgery to remove the lesion in the rectum, the surgical specimen will be examined by the pathologist, who will perform a variety of tests to detect evidence of new blood vessel growth. The sample will be stored per routine protocol of the Stanford Department of Pathology.
|Study Start Date:||November 2011|
|Estimated Study Completion Date:||November 2015|
|Estimated Primary Completion Date:||November 2014 (Final data collection date for primary outcome measure)|
Recent advances in computed tomography (CT) technology have made CT perfusion imaging feasible for the assessment of tumor perfusion in solid tumors of the abdomen. CT perfusion has shown promising results in serving as a noninvasive method of predicting response to therapy in cancer patients. CT perfusion parameters have also been found to correlate with immunohistologic markers of angiogenesis in a number of solid tumors, suggesting a possible role for CT perfusion as a noninvasive biomarker of tumor angiogenesis. The goals of the investigators study are twofold: first, to determine the relationship between baseline CT perfusion characteristics of rectal cancers and their response to treatment, and second, to determine if perfusion CT can be used to subsequently monitor tumor response to treatment. The investigators hope to enroll those patients with locally advanced rectal cancer undergoing standard CT for pre-treatment planning, integrating CT perfusion imaging into the current abdomen/pelvis imaging protocol with close clinical and radiologic follow-up after treatment to determine response to therapy and time to disease progression.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01460641
|United States, California|
|Stanford University Cancer Institute||Recruiting|
|Stanford, California, United States, 94305|
|Contact: Laura Gable 650-736-0798 email@example.com|
|Principal Investigator: Aya Kamaya, MD|
|Principal Investigator:||Aya Kamaya||Stanford University|